Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109316 · ClinicalTrials.gov registry record · Phase 3
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
NCT01109316: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01109316 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 132 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01109316, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
Study Summary
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \[CSII\]) compared to insulin aspart over 6 days of pump reservoir in-use. The study will also compare the in-use characteristics of insulin lispro infused at 6 days with insulin lispro infused at 2 days.
Interventions
- DRUG Insulin lispro 2 day reservoir in-use
- DRUG Insulin lispro 6 day reservoir in-use
- DRUG Insulin aspart 6 day reservoir in-use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT01109316 record still lists
NCT01109316 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Insulin lispro 2 day reservoir in-use is the first listed.
NCT01109316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01109316 about?
NCT01109316 is a clinical study titled "Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use". This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \[CSII\]) compared to insulin aspart over 6 days of pump reservoir in-use. The st...
What is the current status of trial NCT01109316?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2010-04. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01109316?
The interventions under investigation include: Insulin lispro 2 day reservoir in-use (DRUG), Insulin lispro 6 day reservoir in-use (DRUG), Insulin aspart 6 day reservoir in-use (DRUG).
Who is sponsoring clinical trial NCT01109316?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01109316's enrollment target sits among peer trials
132 1588th of 2000 higher than 408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia